1 / 33

Biosimilars in Rheumatoid Arthritis: Clinical Practice Challenges

Explore key issues and challenges in implementing biosimilars in rheumatoid arthritis treatment. Learn about clinical trials, pharmacovigilance, immunogenicity, and patient considerations. Stay informed on FDA proposals and clinician perspectives on switching to biosimilars.

devinm
Download Presentation

Biosimilars in Rheumatoid Arthritis: Clinical Practice Challenges

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Application of Biosimilars in RA IN Clinical Practice:Key Issues and Challenges

  2. Introduction

  3. Differences Between Generics and Biosimilars

  4. Clinical Development Program: Biosimilars

  5. Differences Between Development of New Generics and New Biosimilar Medications

  6. Clinical Trials of Biosimilars

  7. EMA Principles for Establishing Biosimilarity

  8. Postmarketing Pharmacovigilance for Biosimilars

  9. Immune Reactions to Biologic Therapeutics

  10. Considerations in Determining Immunogenicity

  11. Extrapolation to Other Indications

  12. Clinical Study of Rituximab Biosimilar Candidate CT-P10 Performed in RA

  13. Biosimilar Naming and Traceability

  14. FDA Proposal on Biosimilar Nomenclature

  15. Redefining "Switching"

  16. Patient Case 1

  17. Patient Case 1:A Clinician’s Perspective

  18. Cost: Clinician’s Perspective

  19. Starting a Patient on a Biosimilar: Another Clinician’s Perspective

  20. Patient Case 2

  21. Patient and Physician Considerations in a Nonmedical Switch

  22. Physician Considerations:Nonmedical Switch

  23. DANBIO Registry: Effect of Nonmedical Switch From Originator to Biosimilar Infliximab

  24. Adherence Results for the DANBIO Registry After a Nonmedical Switch

  25. Importance of Doctor-Patient Communication

  26. Switching Between Multiple Biosimilars?

  27. Patient Case 3

  28. Adherence in RA:Generally Low for Conventional Treatments

  29. Encouraging Adherence and Informing the Patient

  30. Acceptance of Biosimilars

  31. Concluding Remarks

  32. Abbreviations

More Related